Rep. Gilbert Ray Cisneros, Jr. Sells Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Halozyme Therapeutics stock on March 24th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of PTC NASDAQ: PTC on 4/1/2025.
• Sold $1,001 - $15,000 in shares of W. R. Berkley NYSE: WRB on 4/1/2025.
• Sold $15,001 - $50,000 in shares of GoDaddy NYSE: GDDY on 4/1/2025.
• Purchased $1,001 - $15,000 in shares of Ford Motor NYSE: F on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 3/31/2025.
• Purchased $1,001 - $15,000 in shares of Boeing NYSE: BA on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Hologic NASDAQ: HOLX on 3/31/2025.
• Sold $15,001 - $50,000 in shares of Merck & Co., Inc. NYSE: MRK on 3/31/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/31/2025.

Halozyme Therapeutics Trading Up 4.4 %

HALO stock traded up $2.52 during midday trading on Friday, hitting $60.22. The stock had a trading volume of 1,839,648 shares, compared to its average volume of 1,411,918. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The business has a fifty day moving average price of $60.22 and a two-hundred day moving average price of $54.91. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The firm has a market cap of $7.44 billion, a P/E ratio of 17.56, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the sale, the director now directly owns 33,108 shares in the company, valued at approximately $2,120,567.40. The trade was a 1.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock worth $1,286,568 over the last three months. Company insiders own 2.40% of the company's stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust increased its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 322 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

HALO has been the subject of several research reports. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Finally, Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.